|
Northfield Laboratories worked to develop a blood substitute called PolyHeme as an alternative to transfusion for extreme blood loss. PolyHeme was developed to carry oxygen and restore blood volume without the risk of transmitting such diseases as AIDS or hepatitis and without the need for blood typing. Made from modified human blood hemoglobin, PolyHeme had a longer shelf life than the real stuff. However, in 2009 the FDA rejected the product, citing significant adverse events (a.k.a. patient deaths), and lack of clear clinical benefits. Following that decision, Northfield reviewed its options and chose to close all of its operations in 2009. Shortly thereafter the company filed for Chapter 11 bankruptcy.
|
| | | Contact Information | |
Address: |
1560 Sherman Ave., Ste. 1000
Evanston, IL 60201-4800
| | Phone: | 847-635-0066 | | Fax: | |
|
| Financial
Highlights | | Fiscal Year End: | May | | Revenue (2008): | 0.00 M | | Employees (2008): | 91 | | Employee Growth (1 yr): | (-2.20%) |
|
|
Key People
| | • |
Chairman and CEO:
Steven A. Gould
| | • |
SVP Operations:
Robert L. McGinnis
| | • |
CTO:
Marc D. Doubleday
|
|
|
